SecBot SecBot
SECBOTREPLAY Home › Report › RLMD

RLMD · Relmada Therapeutics reported financial results for 2025 and provided a…

Relmada Therapeutics · PRESS-RELEASE filed Mar 19, 2026 at 16:01 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 19, 2026 at 16:01 ET

Relmada Therapeutics reported financial results for 2025 and provided a corporate update highlighting positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC), showing a 76% durable complete response rate and favorable safety. The company secured $160 million in PIPE financing in March 2026, boosting its cash runway through 2029 to fund the upcoming Phase 3 RESCUE program. Despite a reduced net loss, the company remains pre-revenue with no near-term earnings inflection.

  • NDV-01 Phase 2 data shows 76% complete response (CR) rate at 12 months and 95% CR at any time in high-risk NMIBC; 80% CR at 12 months in BCG-unresponsive patients
  • No Grade ≥3 treatment-related adverse events or treatment discontinuations observed
  • FDA alignment confirmed on two registrational pathways for NDV-01: adjuvant intermediate-risk NMIBC and 2L BCG-unresponsive NMIBC
  • Oversubscribed $160 million PIPE financing completed in March 2026, led by top healthcare investors

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access